Subscribe to our Newsletters !!
Few developments in science and technology have be
Biotech Fluidics offers a range of non-invasive fl
The recent rabies death of an 11 year old Canadian
Cipla Limited (BSE: 500087; NSE: CIPLA EQ; and her
Generic medicines have become a cornerstone in hea
Tofu used to be associated with Asian cuisine, but
Dear Readers, Welcome to the latest issue of Micro
The he last two decades have seen major changes in the biopharmaceutical industry. The importance of single-use systems (SUS) has grown from being specialty tools in a lab to critical infrastructures in the development and large-scale production of vaccines and biologics.
A modern-day bioprocess can have in excess of hundreds of single-use components such as tubing, connectors, clamps, bags, filters, and other molded components, as well as commercial assemblies and customized fluid transfer systems.
While these systems are referred to as consumables, they carry a significant burden on product quality, manufacturing reliability, compliance to regulations, and safety of the end-user. Potential issues with any one of these systems can halt production of a million-dollar batch, cause concern for leachables, and impose an integrity risk to the manufacturing process. Even a minor disruption to the supply chain of any one of these plastic products can result in delays in providing much-needed therapies to the patients.
Because of this burden, biopharmaceutical companies have begun to view suppliers of these single-use components as quality-driven partners for manufacturing plastic components in contrast to plastic molders of the past.
This emerging view has led to the increasing application of the principles of Quality by Design (QbD) to the manufacturing of consumables. QbD, which originated in pharmaceutical development and was formalized in the International Council for Harmonisation (ICH) guidelines, describes a science- and risk-driven approach to the design and manufacture of products and processes to ensure quality.
For producers of bioprocessing consumables, QbD gives the opportunity to create predictable quality and robust manufacturing with a high degree of confidence from regulators and differentiates competitively in a sustainable manner. Producers of single-use bioprocessing components will not gain the market advantage by producing the cheapest components.
The advantage will go to producers of single-use components who understand the materials, processes, risks, variability, and lifecycle of their components.
Traditionally, some producers of single-use components were manufacturers of plastics, rubbers, and other extrusions and mouldings. Their core capabilities were efficient manufacturing, cost and time to market, and expertise in fabrication and molding.
These will continue to be important, however biopharmaceutical clients are expecting more. Today, supplier qualification processes will assess a variety of criteria, including, but not limited to, quality and change control, traceability and risk, validation, data integrity, and regulatory acceptance.
This is not without reason. Biopharmaceutical clients are more and more expecting their suppliers to adopt quality by design philosophy, as single-use components are interacting with drug substances and conducting critical operations in sterile environments.
The industry is adopting the philosophy of “quality cannot be inspected into a single-use component.” It must be designed both in the component and the manufacturing process.
QbD in single-use components encompasses a structured development process with an end goal in mind that focuses on the science and quality of the process to manage risks.
For consumable manufacturers, QbD refocuses from finding flaws to minimizing them. Instead of saying, “Did this part pass the inspection?” QbD asks (a) what part of the process is most important to the customer? (b) what factors and/or features of the process impact the response? (c) what is the acceptable range of variability? and, (d) how can the process best define and control the acceptable response? a big theory of QbD is developing a scientific methodology to design and control a process with the end goal of having predictability, reliability, and assurance.
Material selection is the first step in designing a single-use component. In the pharmaceutical QbD framework, Critical Material Attributes (CMAs) are the dimensions and/or characteristics of the raw material that dictate the quality of the final product.
The CMAs of a single-use component can include (a) polymer characteristics (those that affect molecular weight distribution, melt flow index, density and other polymer characteristics), (b) polymer mechanical properties (tensile strength, elongation, flexibility, compression resistance, and others), (c) an extractable and leachable chemical profile and other properties (chemical compatibility, oxidation resistance, and others), (d) biocompatibility (those tested per USP <88> and ISO 10993 including the cytotoxicity), and (e) effects of various methods of sterilization (gamma, e-beam, autoclaving, and others).
A QbD based supplier does not just buy some resin from an authorized supplier. Rather, they gain an understanding of how different material attributes impact the performance of the product. This understanding is the basis for material requirements, supplier assessments, incoming inspections and other operational processes.
Manufacturers must expend hard resources to understand which of the CQAs and/or attributes actually impact the customer experience. When using a Quality by Design (QbD) approach, these resources and efforts are placed on the most impactful CQAs, which are determined using a risk based methodology.
With a deep understanding of CQAs, the manufacturers’ next step is to understand the variables of the process that impact the CQAs.These variables are called Critical Process Parameters (CPPs). For injection molding, temperature, pressure and time can be critical process parameters.
The same concepts of QbD apply to CPPs in that the information and understanding of CQAs and CPPs is used to impact process variables to ultimately impact the performance of the product rather than controlling variables simply because it is the norm.
DotE (Design of Experiments) is considered to be one of the most important tools that aid QbD (Quality by Design). The traditional techniques of process development require one to painstakingly make adjustments to the process, using trial-and-error to reach the desired process. DoE in contrast, gives a systematic scientific order to the understanding of main effects, interaction effects, the basis of variability, and the sensitivity of the process.
To illustrate, consider the molded connector. This may be investigated using a fractional factorial design to examine the effects of molding temperature, the effects of injection pressure, and the effects of the length of the cooling time. The data generated would allow the identification of critical factors, interaction effects, the adequate and acceptable limits of the process, and the robustness of the process.
The result of this study would provide a scientifically justified design space which is far better than the arbitrary limits of the operating conditions.
In conventional manufacturing of plastics, the acceptance of a mold is usually a compliance check of the mold’s dimensional conformity. In contrast, the requirements of bioprocessing are significantly advanced.
Mold validation in bioprocessing should address the question of consistency (can the mold produce acceptable parts repeatedly?), variability (will the performance of the mold remain consistent across different operators, shifts, and equipment?), molding capability (will the mold maintain the required specifications under normal conditions of production?), and mold life (will the performance of the mold be acceptable for the entire life of the tool?). Once molds are validated, they serve the role of quality assets as opposed to simply production equipment. This is highly relevant because even minor variations in tool design can influence the performance of sterile assembly significantly.
Pharmaceutical manufacturers routinely validate production processes. Customers increasingly expect consumable suppliers to follow similar principles. Process validation generally includes:
Applying this framework to component manufacturing improves consistency while strengthening customer confidence. Validation shifts discussions from claims to evidence.
Quality organizations increasingly use process capability metrics to assess manufacturing performance. Two commonly used metrics include Cp and Cpk. These indicators quantify how well a process operates relative to specification limits. A capable process exhibits low variability, stable centering, and predictable output.
Many pharmaceutical customers increasingly expect evidence that critical dimensions are manufactured within statistically capable processes. Process capability demonstrates scientific process control, manufacturing maturity, and reduced quality risk. It transforms quality conversations from subjective opinions to objective data.
One of the most important transitions in modern manufacturing is moving from defect detection to defect prevention. Statistical Process Control (SPC) provides this capability. SPC uses real-time data to identify trends before defects occur. Control charts, trend analysis, process capability studies, pareto analysis, and statistical alarms are common tools used in this context.
For single-use component manufacturers, SPC may monitor critical dimensions, weld strength, pressure resistance, leak test performance, and material properties rather than discovering problems after production is complete, SPC enables proactive intervention. This reduces scrap, rework, customer complaints, and batch failures. Most importantly, it creates a culture of continuous quality improvement.
A common misconception is that quality ends once a product is released. In QbD philosophy, quality management extends throughout the product lifecycle. Lifecycle quality management includes (a) material lifecycle control, covering supplier qualification, material monitoring, change notification, etc., (b) process lifecycle control, covering process trending, revalidation, equipment maintenance, etc., (c) product lifecycle monitoring, covering customer feedback, complaint analysis, performance monitoring, etc., and (d) continuous improvement, covering CAPA implementation, risk reduction, process optimization, etc.
The objective is maintaining a state of control throughout the commercial life of the product. This approach aligns closely with regulatory expectations and customer requirements.
One of the greatest concerns among biopharmaceutical manufacturers is uncontrolled change. A seemingly minor modification involving resin supplier, or mould insert, or assembly process, or sterilization provider may trigger requalification, risk assessments, regulatory filings, and validation activities.
QbD organizations implement rigorous change control systems that evaluate potential impact before implementation. Such systems provide customers with transparency, predictability, and confidence. In many cases, strong change control programs become decisive factors during supplier selection.
QbD and risk management are inseparable. Risk assessments help prioritize resources toward areas with greatest potential impact. Common methodologies for risk assessment are failure Mode and Effects Analysis (FMEA), hazard analysis, risk ranking, and fault tree analysis. Risk-based thinking enables organizations to focus on critical dimensions, critical materials, critical suppliers, and critical processes. Rather than attempting to control everything equally, resources are directed toward the variables that matter most.
Quality investments are sometimes viewed as costs. Leading organizations understand they are strategic investments.
It is important to consider the financial consequences of a single component failure, which could be either batch rejection, or manufacturing downtime, or investigation costs, or regulatory scrutiny, or customer dissatisfaction, or lost market share, or all and few of these.Conversely, robust QbD programs generate measurable business value, in terms of reduced cost of poor quality (fewer defects and complaints), improved manufacturing efficiency (lower scrap and rework), faster customer qualification (scientific evidence accelerates supplier approval), stronger customer retention (confidence strengthens partnerships), premium market positioning (quality leaders compete on value rather than price alone). The economic impact often far exceeds the cost of implementing advanced quality systems.
Perhaps the most important strategic implication of QbD is market differentiation. Traditional moulders typically compete on cost, capacity, and lead time. These factors remain important but are increasingly insufficient in biopharmaceutical markets.
A QbD-driven manufacturer competes on scientific understanding – deep knowledge of materials and processes, regulatory readiness – alignment with pharmaceutical expectations, predictable performance – data-supported reliability, risk reduction -lower operational uncertainty, lifecycle support – partnership throughout product life.
The distinction is profound. A conventional moulder sells parts. A QbD-driven supplier delivers confidence. As biopharmaceutical manufacturing becomes increasingly sophisticated, confidence becomes a highly valuable product.
The next generation of bioprocessing suppliers will increasingly resemble pharmaceutical manufacturers in their quality philosophy. Digital quality systems, real-time process analytics, predictive quality monitoring, advanced process capability management, AI-driven quality intelligence, and digital twins for process optimization are current emerging trends.
Customers increasingly expecting suppliers to demonstrate Process understanding of statistical control, scientific validation, and lifecycle management.
Organizations that embrace these principles early will establish sustainable competitive advantages. Those that continue operating as conventional plastics manufacturers risk being excluded from high-value biopharmaceutical supply chains.
The rapid expansion of single-use technologies has fundamentally elevated the role of consumable manufacturers within the biopharmaceutical ecosystem. Single-use components are no longer simple plastic parts; they are critical enablers of product quality, manufacturing efficiency, regulatory compliance, and ultimately patient safety.
Quality by Design provides a powerful framework for meeting these elevated expectations. By systematically understanding Critical Material Attributes, Critical Quality Attributes, Critical Process Parameters, mould behaviour, process capability, statistical control, and lifecycle performance, manufacturers can build quality into their products rather than attempting to inspect defects out of them. More importantly, QbD transforms the strategic identity of a company. It shifts the organization from being viewed as a commodity supplier to being recognized as a trusted quality partner.
In an industry where the consequences of failure can be measured in millions of dollars and potentially impact patient lives, that distinction matters enormously.
The future winners in single-use manufacturing will not simply be the companies that mould components most efficiently. They will be the companies that combine engineering excellence, scientific rigor, pharmaceutical quality thinking, and lifecycle quality management to deliver confidence at every stage of the bioprocessing journey.
Author: Priyabrata Pattnaik
Chief Executive Officer (CEO)
[email protected]
